Combinatorial protein engineering of proteolytically resistant mesotrypsin inhibitors as candidates for cancer therapy

Lignende værker

• Disulfide engineering of human Kunitz-type serine protease inhibitors enhances proteolytic stability and target affinity toward mesotrypsin
  af: Cohen, Itay, et al.
  Udgivet: (2019)
• A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering
  af: Sananes, Amiram, et al.
  Udgivet: (2018)
• Mesotrypsin Has Evolved Four Unique Residues to Cleave Trypsin Inhibitors as Substrates
  af: Alloy, Alexandre P., et al.
  Udgivet: (2015)
• Mapping protein selectivity landscapes using multi-target selective screening and next-generation sequencing of combinatorial libraries
  af: Naftaly, Si, et al.
  Udgivet: (2018)
• The P(2)′ residue is a key determinant of mesotrypsin specificity: Engineering a high affinity inhibitor with anticancer activity
  af: Salameh, Moh’d A., et al.
  Udgivet: (2011)